DiagnosTear Ltd. – Clinical Trial for the purpose of examining a potential commercial cooperation for the DiagnosTear’s TeaRx™ Product

Tel Aviv (June 21, 2020) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. (“DiagnosTear“)[1], that is engaged in research, development and commercialization of a product that is based on DiagnosTear’s TeaRx ™ technology, which is used today to diagnose, personalize treatment and monitor dry eye …

Continue reading

BioLight’s New Investment in Belkin Laser Ltd., a medical device company which develops an innovative one-second Glaucoma laser treatment

Tel Aviv (December 22, 2019) – BioLight is pleased to announce that today, it has signed a binding agreement for its investment in Belkin Laser Ltd. (the “Agreement” and “Belkin Laser”). According to the Agreement, BioLight shall invest approx. USD 1M in consideration for the issuance of Preferred B shares …

Continue reading

DiagnosTear Ltd. – Approval to register patent to its TeaRx ™ technology by the United States Patent and Trademark Office (USPTO)

Tel Aviv (October 15, 2019) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. (“DiagnosTear“)[1], that is engaged in research, development and commercialization of a product that is based on DiagnosTear’s TeaRx ™ technology, which is used to diagnose, personalize treatment and monitor dry eye syndrome …

Continue reading

BioLight’s New Investment in Tarsius Pharma Ltd. that develops a novel platform for the treatment of blinding ocular diseases

Tel Aviv (October 6, 2019) – BioLight is pleased to announce that on October 3, 2019, it has signed a binding Simple Agreement for Future Equity (SAFE), together with other investors, for investment in Tarsius Pharma Ltd. (the “Agreement” and “Tarsius”), a private Israeli company developing a novel platform for …

Continue reading